34655 Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2022
This article has no abstract
Epistemonikos ID: 4ff3f8e1d5e3cc51d577d8c3101528da946d4d84
First added on: Feb 15, 2025